7.3.2. distant metastases. 7.3.2.1. systemic treatments - first-line setting 7.3.2.1.1. enfortumab vedotin + pembrolizumab combination therapy 23 years despite multiple attempts new agents and/or combinations treatments, platinum-based chemotherapy remained standard care previously untreated advanced metastatic urothelial cancer. october 2023, landscape changed dramatically ev302 phase iii randomised multi-centre study. compared combination nectin 4 directed antibody-drug conjugate enfortumab vedotin check point inhibitor pembrolizumab, (ev+p) platinum based combination chemotherapy (gemcitabine-cisplatin gemcitabine -carboplatin. see table 2 definition cisplatin eligibility). study showed significant improvement pfs ( hr 0.45 (0.38-0.54 ) os (hr 0.47 (0.38-0.58) rr 68% (versus 44%) cr 29% . os benefit seen across sub groups regardless cisplatin eligibility. common grade 3 trae special interest included skin reactions (15.5%) , peripheral neuropathy (6.8%) hyperglycaemia (6.1%). proportion utuc patients study yet known. sequencing treatment ev+pembro currently unclear later line treatments depend upon agents patient previously received (figure 7.3). 7.3.2.1.2. patients ineligible ev+pembro fit cisplatin-based combination chemotherapy upper tract uc urothelial bc respond systemic platinum-based chemotherapy. eligibility platinum-based chemotherapy metastatic setting based criteria outlined table 2. retrospective analysis three rcts showed primary tumour location lower- upper urinary tract impact progression-free survival (pfs) os patients locally-advanced metastatic uc treated platinum-based combination chemotherapy . therefore, cisplatin-containing combination chemotherapy standard treatment advanced metastatic utuc ineligible ev + pembro . number cisplatin-containing chemotherapy regimens proven efficacy although gemcitabine cisplatin widely used. use cisplatin-based chemotherapy widely considered patients egfr > 45 ml/min . efficacy immunotherapy using pd1 pd-l1 inhibitors evaluated first-line setting treatment cisplatin/carboplatin-fit patients metastatic uc, including utuc . first-line immune checkpoint inhibitors combination platinum-based chemotherapy immune checkpoint inhibitors previously resulted positive significant survival advantages thus previously recommended [295-297]. studies included cisplatin carboplatin combinations. phase iii rct advanced/metastatic urothelial cancer shown overall benefit addition nivolumab chemotherapy (gemcitabine-cisplatin). median os improved (21.7 months v 18.9 months hr 0.78 (0.63-0.96) well median pfs (7.9 months versus 7.6 months hr 0.72 (0.59-0.88). objective rr 57.6% compared 43.1 % chemotherapy alone . although sub-group analysis based tumour position study, 12.6% patients utuc. 7.3.2.1.3. patients ineligible ev+pembro unfit cisplatin-based combination chemotherapy carboplatin-based chemotherapy recommended patients unfit cisplatin . carboplatin gemcitabine preferred regimen , irrespective pdl-1 status. recent critical re-analysis rcts comparing os cisplatin vs. carboplatin-based regimens advanced uc, cisplatin conferred minor os benefit compared carboplatin . 7.3.2.1.4. maintenance therapy first-line platinum-based chemotherapy maintenance avelumab recommended patients complete/partial response stable disease 4–6 cycles platinum-based chemotherapy, given first line setting only. data phase iii rct showed use avelumab maintenance therapy 4 6 cycles gemcitabine plus cisplatin carboplatin (started within 10 weeks completion first-line platinum-based chemotherapy) significantly prolonged os compared best supportive care alone patients advanced metastatic uc experience disease progression during, responded to, first-line chemotherapy (hr: 0.69; 95% ci: 0.56–0.86) . increase median os 14 21 months observed avelumab. although subgroup analysis based tumour location available study, almost 30% included patients utuc. similarly, phase ii study comprising 108 patients metastatic uc achieving least stable disease first-line platinum-based chemotherapy, maintenance pembrolizumab improved pfs compared placebo (5.4 vs. 3.0 months) . 7.3.2.1.5. patients unfit combination therapy pembrolizumab atezolizumab alternative choices patients pd-l1 positive eligible/ fit platinum-based chemotherapy. single-arm phase ii trial (n = 370) cisplatin-ineligible uc, pembrolizumab monotherapy associated objective response rate 26% 69 metastatic utuc patients . overall cohort, pd-l1 expression 10% associated greater response rate pembrolizumab. treatment-related toxicity line previous studies. single-arm phase ii trial (n = 119) cisplatin-ineligible uc, atezolizumab monotherapy associated objective response rate 39% 33 (28%) metastatic utuc patients . median os overall cohort 15.9 months treatment-related toxicity line previous studies . 7.3.2.2. systemic treatments - later line setting subsequent treatments depend type treatment given first line setting. 7.3.2.2.1. platinum based chemotherapy platinum based chemotherapy second line treatment choice received first line setting. data supports use maintenance avelumab outside first line setting. 7.3.2.2.2. immunotherapy phase iii rct including 542 patients received prior platinum-based chemotherapy advanced uc showed pembrolizumab decreased risk death compared second-line chemotherapy (the investigator’s choice paclitaxel, docetaxel, vinflunine); median os: 10.3 months pembrolizumab 7.4 months chemotherapy (hr: 0.73; 95% ci: 0.59–0.91) . responses frequent durable pembrolizumab compared chemotherapy (21% vs. 11%). utuc subgroup (n = 75/13.8%), os benefit seemed larger (50%). imvigor211 trial explored atezolizumab pd-l1-positive tumours patients tumours relapsed platinum-based chemotherapy; failed show significant os advantage atezolizumab compared second-line chemotherapy . immunotherapies nivolumab , avelumab durvalumab shown objective response rates ranging 17.8% 19.6% median os ranging 7.7 months 18.2 months patients platinum-resistant metastatic uc. results obtained single- arm phase ii trials number utuc patients included studies specified avelumab (n = 7/15.9%) without subgroup analysis based primary tumour location . immunotherapy combination nivolumab plus ipilimumab shown significant anti-tumour activity objective response rate 38% phase i/ii multicentre trial including 78 patients metastatic uc experiencing disease progression platinum-based chemotherapy . although utuc patients included trial, subgroup analysis available. immunotherapy combinations may effective second-line setting data currently limited . 7.3.2.2.3. novel agents fibroblast growth factor receptors (fgfr) inhibition erdafitinib, pan-fgfr tyrosine kinase inhibitor fgfr1–4, associated 40% radiological response rate according response evaluation criteria solid tumours (recist) phase ii trial 99 patients locally-advanced metastatic uc progressed first-line chemotherapy harboured fgfr dna genomic alterations (fgfr2/3 fusions fgfr3 mutations) . study included 23 utuc patients visceral metastases showing 43% radiological response rate. subsequent phase iii thor trial randomised 266 patients advanced uc similar mutations experienced disease progression 1-2 lines previous treatment, treatment either erdafitinib investigators choice chemotherapy (vinfunine docetaxel). significant improvements median os, (4.3 months; hr 0.64;ci 0.47-0.88), pfs 2.9 months (58; ci 0.44-0.78) 36% risk reduction death observed. 33.5 % patient study utuc . rate activating alterations fgfr3 higher utuc bladder cancer potentially greater impact fgr3 targeting agents anticipated. utuc patients tested fgfr alterations (fgfr2/3 mutations fgfr3 fusions) prior erdafitinib treatment. antibody drug conjugates (adc) phase ii study enrolled 89 patients (of 43% utuc) cisplatin-unfit metastatic uc experiencing disease progression therapy pd-1 pd-l1 inhibitors. patients received antibody–drug conjugate enfortumab vedotin. objective radiological response rate (recist) 52% 20% patients achieved complete response . phase iii trial enfortumab vedotin treatment patients locally- advanced metastatic uc previously received platinum-containing chemotherapy disease progression treatment pd-1 pd-l1 inhibitor, enfortumab vedotin significantly prolonged survival compared standard chemotherapy (median os 12.88 vs. 8.97 months) . open-label phase ii trial total 108 patients metastatic uc progressed platinum- based chemotherapy checkpoint inhibitors treated antibody-drug conjugate sacituzumab govitecan. objective radiological response rate 27%, median duration response 7.2 months, median pfs 5.4 months median os 10.9 months. however, proportion patients utuc mentioned publication . pre-planned subgroup analysis phase iii range trial assessed impact outcomes safety ramucirumab added docetaxel disease progression platinum-based chemotherapy immune checkpoint inhibitors . median pfs 3.15 months ramucirumab/docetaxel vs. 2.73 months placebo/docetaxel (hr: 0.786; 95% ci: 0.404–1.528, p = 0.4877). trend ramucirumab benefit occurred despite ramucirumab arm higher percentage patients poorer prognosis. however, findings need confirmation studies, analysis limited patient numbers imbalance treatment arms. 7.3.2.3. surgery 7.3.2.3.1. radical nephroureterectomy data regarding rnu metastatic setting lacking mainly retrospective observational studies [320-322]. although evidence remains limited, rnu may associated css os benefit selected patients, especially fit enough receive cisplatin-based chemotherapy . noteworthy benefits may limited patients one metastatic site . nonetheless, given high risk bias observational studies addressing rnu metastatic utuc, indications rnu setting mainly reserved palliative patients, aimed controlling symptomatic disease . 7.3.2.3.2. metastasectomy utuc-specific study supporting role metastasectomy patients advanced disease. reports suggesting resection metastatic lesions could safe oncologically beneficial selected patients interpreted caution [325-329]. absence data rcts, patients evaluated individual basis decision perform metastasectomy (surgically) made following shared decision-making process patient. figure 7.3 flowchart management metastatic upper tract urothelial carcinoma*in view lack subgroup analysis data utucev = enfortumab vedotin; fgfr = fibroblast growth factor receptor; gfr = glomerular filtration rate; ps = performance status; cpi=checkpoint inhibitor; pd-l1= programmed death-ligand 1; pd= programmed death